Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Harrison C. Bergeron & Ralph A. Tripp. (2022) Breakthrough therapy designation of nirsevimab for the prevention of lower respiratory tract illness caused by respiratory syncytial virus infections (RSV). Expert Opinion on Investigational Drugs 31:1, pages 23-29.
Read now
Read now
Antonio Del Vecchio, Teresa Ferrara, Marco Maglione, Letizia Capasso & Francesco Raimondi. (2013) New perspectives in Respiratory Syncitial Virus infection. The Journal of Maternal-Fetal & Neonatal Medicine 26:sup2, pages 55-59.
Read now
Read now
Parthiv J. Mahadevia, Anthony S. Masaquel, Mark J. Polak & Leonard B. Weiner. (2012) Cost utility of palivizumab prophylaxis among pre-term infants in the United States: a national policy perspective. Journal of Medical Economics 15:5, pages 987-996.
Read now
Read now
Leonard B. Weiner, Anthony S. Masaquel, Mark J. Polak & Parthiv J. Mahadevia. (2012) Cost-effectiveness analysis of palivizumab among pre-term infant populations covered by Medicaid in the United States. Journal of Medical Economics 15:5, pages 997-1018.
Read now
Read now
Julia M Hussman, Abby Li, Bosco Paes & Krista L Lanctôt. (2012) A review of cost–effectiveness of palivizumab for respiratory syncytial virus. Expert Review of Pharmacoeconomics & Outcomes Research 12:5, pages 553-567.
Read now
Read now
Kelly A. Smart, Bosco A. Paes & Krista L. Lanctôt. (2010) Changing costs and the impact on RSV prophylaxis. Journal of Medical Economics 13:4, pages 705-708.
Read now
Read now
Articles from other publishers (24)
Mary T. Caserta, Sean T. O’Leary, Flor M. Munoz, Shawn L. Ralston, Sean T. O’Leary, James D. Campbell, Monica I. Ardura, Ritu Banerjee, Kristina A. Bryant, Mary T. Caserta, Jeffrey S. Gerber, Chandy C. John, Athena P. Kourtis, Angela Myers, Pia Pannaraj, Adam J. Ratner, José R. Romero, Samir S. Shah, Kenneth M. Zangwill, Yvonne A. Maldonado, Flor M. Munoz, Shawn L. Ralston, David W. Kimberlin, Elizabeth D. Barnett, Ruth Lynfield, Mark H. Sawyer, Henry H. Bernstein, Karen M. Farizo, Lisa M. Kafer, David Kim, Eduardo López Medina, Denee Moore, Lakshmi Panagiotakopoulos, Laura Sauvé, Jeffrey R. Starke, Jennifer Thompson, Kay M. Tomashek, Melinda Wharton, Charles R. WoodsJr.Jr. & Jennifer M. Frantz. (2023) Palivizumab Prophylaxis in Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics.
Crossref
Crossref
Estefany Rios Guzman & Judd F. Hultquist. (2022) Clinical and biological consequences of respiratory syncytial virus genetic diversity. Therapeutic Advances in Infectious Disease 9, pages 204993612211280.
Crossref
Crossref
Lauren Alexandra Quinn, Michael D. Shields, Ian Sinha & Helen E. Groves. (2020) Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a systematic review. Systematic Reviews 9:1.
Crossref
Crossref
Jesse Papenburg, Mahwesh Saleem, Johannes Teselink, Abby Li, Georges Caouette, Édith Massé & Krista L. Lanctôt. (2020) Cost-analysis of Withdrawing Immunoprophylaxis for Respiratory Syncytial Virus in Infants Born at 33–35 Weeks Gestational Age in Quebec. Pediatric Infectious Disease Journal 39:8, pages 694-699.
Crossref
Crossref
Gilber Kask, Lauri Raittio, Ville M. Mattila & Antti P. Launonen. (2020) Cost-Effectiveness of Operative Versus Non-Operative Treatment for Clavicle Fracture: a Systematic Literature Review. Current Reviews in Musculoskeletal Medicine 13:4, pages 391-399.
Crossref
Crossref
Lauren Alexandra Quinn, Michael D. Shields & Helen E. Groves. (2019) Respiratory syncytial virus prophylaxis for prevention of recurrent childhood wheeze and asthma: a protocol for a systematic review. Systematic Reviews 8:1.
Crossref
Crossref
Stephen MacAmanda SumnerSamuel Duchesne-BelangerRobert StirlingMatthew TunisBeate Sander. (2019) Cost-effectiveness of Palivizumab for Respiratory Syncytial Virus: A Systematic Review. Pediatrics 143:5.
Crossref
Crossref
Manjiri Joshi & Robert M R Tulloh. (2018) Respiratory virus prophylaxis in congenital heart disease. Future Cardiology 14:5, pages 417-425.
Crossref
Crossref
Song Feng, Chao Li, Dongdong Chen, Xiufang Zheng, Hongying Yun, Lu Gao & Hong C. Shen. (2017) Discovery of methylsulfonyl indazoles as potent and orally active respiratory syncytial Virus(RSV) fusion inhibitors. European Journal of Medicinal Chemistry 138, pages 1147-1157.
Crossref
Crossref
Shuenn-Nan Chiu, Pei-Lan Shao, Hui-Chi Chen, Ming-Tai Lin, Li-Min Huang, Feng-Yu Kao, San-Kuei Huang, Jou-Kou Wang & Mei-Hwan Wu. (2016) Risk of Respiratory Syncytial Virus Infection in Cyanotic Congenital Heart Disease in a Subtropical Area. The Journal of Pediatrics 171, pages 25-30.e1.
Crossref
Crossref
Michael B Battles, Johannes P Langedijk, Polina Furmanova-Hollenstein, Supranee Chaiwatpongsakorn, Heather M Costello, Leen Kwanten, Luc Vranckx, Paul Vink, Steffen Jaensch, Tim H M Jonckers, Anil Koul, Eric Arnoult, Mark E Peeples, Dirk Roymans & Jason S McLellan. (2015) Molecular mechanism of respiratory syncytial virus fusion inhibitors. Nature Chemical Biology 12:2, pages 87-93.
Crossref
Crossref
Joan L Robinson & Nicole Le Saux. (2015) Prévenir les hospitalisations pour l’infection par le virus respiratoire syncytial. Paediatrics & Child Health 20:6, pages 327-333.
Crossref
Crossref
Leanne M.A. Kool-Houweling, Fernie J.A. Penning-van Beest, Irene D. Bezemer, Richard A. van Lingen & Ron M.C. Herings. (2015) Infants born before 32 weeks of gestation or with respiratory disease are most likely to receive palivizumab in the Netherlands. Acta Paediatrica 104:9, pages 927-932.
Crossref
Crossref
Paul M. Brown, Dana L. Schneeberger & Giovanni Piedimonte. (2015) Biomarkers of respiratory syncytial virus (RSV) infection: specific neutrophil and cytokine levels provide increased accuracy in predicting disease severity. Paediatric Respiratory Reviews 16:4, pages 232-240.
Crossref
Crossref
Benedict U. Nwachukwu, William W. Schairer, Evan O’Dea, Frank McCormick & Joseph M. Lane. (2015) The Quality of Cost-Utility Analyses in Orthopedic Trauma. Orthopedics 38:8.
Crossref
Crossref
Joan L Robinson & Nicole Le Saux. (2015) Preventing hospitalizations for respiratory syncytial virus infection. Paediatrics & Child Health 20:6, pages 321-326.
Crossref
Crossref
C. Carrie Liu, Justin Lui, Elizabeth Oddone Paolucci & Luke Rudmik. (2014) Systematic Review of the Quality of Economic Evaluations in the Otolaryngology Literature. Otolaryngology–Head and Neck Surgery 152:1, pages 106-115.
Crossref
Crossref
Javier Díez-Domingo, Eduardo G Pérez-Yarza, José A Melero, Manuel Sánchez-Luna, María Dolores Aguilar, Antonio Javier Blasco, Noelia Alfaro & Pablo Lázaro. (2014) Social, economic, and health impact of the respiratory syncytial virus: a systematic search. BMC Infectious Diseases 14:1.
Crossref
Crossref
Gang Luo, Flory L. Nkoy, Per H. Gesteland, Tiffany S. Glasgow & Bryan L. Stone. (2014) A systematic review of predictive modeling for bronchiolitis. International Journal of Medical Informatics 83:10, pages 691-714.
Crossref
Crossref
Michael T. Brady, Carrie L. Byington, H. Dele Davies, Kathryn M. Edwards, Mary Anne Jackson, Yvonne A. Maldonado, Dennis L. Murray, Walter A. Orenstein, Mobeen H. Rathore, Mark H. Sawyer, Gordon E. Schutze, Rodney E. Willoughby, Theoklis E. Zaoutis, Shawn L. Ralston, Allan S. Lieberthal, H. Cody Meissner, Brian K. Alverson, Jill E. Baley, Anne M. Gadomski, David W. Johnson, Michael J. Light, Nizar F. Maraqa, Eneida A. Mendonca, Kieran J. Phelan, Joseph J. Zorc, Danette Stanko-Lopp & Sinsi Hernández-Cancio. (2014) Updated Guidance for Palivizumab Prophylaxis Among Infants and Young Children at Increased Risk of Hospitalization for Respiratory Syncytial Virus Infection. Pediatrics 134:2, pages e620-e638.
Crossref
Crossref
Andrew HiattNatasha BohorovaOgnian BohorovCharles GoodmanDo KimMichael H. PaulyJesus VelascoKevin J. WhaleyPedro A. Piedra, Brian E. Gilbert & Larry Zeitlin. (2014) Glycan variants of a respiratory syncytial virus antibody with enhanced effector function and in vivo efficacy. Proceedings of the National Academy of Sciences 111:16, pages 5992-5997.
Crossref
Crossref
Javier Soto ÁlvarezJavier Soto Álvarez. 2012. Evaluación económica de medicamentos y tecnologías sanitarias:. Evaluación económica de medicamentos y tecnologías sanitarias:
277
292
.
Bosco Paes & Paolo Manzoni. (2011) Special populations: Do we need evidence from randomized controlled trials to support the need for respiratory syncytial virus prophylaxis?. Early Human Development 87, pages S55-S58.
Crossref
Crossref
Nam Kyun KimJae Young Choi. (2011) Respiratory syncytial virus prevention in children with congenital heart disease: who and how?. Korean Journal of Pediatrics 54:5, pages 197.
Crossref
Crossref